Elite Pharmaceuticals Inc Stock OTC Bulletin Board
Equities
US28659T2006
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 02 | Transcript : Elite Pharmaceuticals, Inc., Q4 2024 Earnings Call, Jul 02, 2024 | |
Jul. 01 | Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Financials (USD)
Sales 2023 | 34.16M | Sales 2024 | 56.63M | Capitalization | 157M |
---|---|---|---|---|---|
Net income 2023 | 3M | Net income 2024 | 20M | EV / Sales 2023 | 0.75 x |
Net cash position 2023 | 3.94M | Net Debt 2024 | 4.63M | EV / Sales 2024 | 2.86 x |
P/E ratio 2023 |
9.34
x | P/E ratio 2024 |
7.79
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 |
-
| Free-Float | 73.16% |
Latest transcript on Elite Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Nasrat Hakim
CEO | Chief Executive Officer | 63 | 13-07-31 |
Christopher Dick
CEO | Chief Executive Officer | 69 | 02-10-31 |
Carter Ward
DFI | Director of Finance/CFO | 59 | 09-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Whitnell
BRD | Director/Board Member | 68 | 09-10-22 |
Barry Dash
BRD | Director/Board Member | 93 | 05-03-31 |
Davis Caskey
BRD | Director/Board Member | 76 | 16-04-27 |
1st Jan change | Capi. | |
---|---|---|
+25.24% | 45.32B | |
+34.85% | 24.51B | |
+29.56% | 16.85B | |
+21.32% | 14.62B | |
+70.51% | 14.16B | |
-0.05% | 6.79B | |
+15.74% | 5.82B | |
-8.87% | 5.73B | |
+10.29% | 4.93B |